The University of Colorado Comprehensive Cancer Center (CU Cancer Center) and Flatiron Health have joined forces to revolutionize the efficiency of clinical trials by significantly reducing the administrative workload traditionally placed on researchers. By integrating Flatiron Clinical Pipe with
The pharmaceutical industry is abuzz with excitement over a new class of cancer drugs known as PD-1/VEGF inhibitors. These promising therapies, currently undergoing clinical trials, might leapfrog Merck & Co.’s highly successful cancer immunotherapy, Keytruda. The advent of these new drugs could
Parkinson's disease, a devastating neurodegenerative disorder, is characterized by the relentless loss of dopaminergic neurons, which leads to significant motor dysfunction and a decline in overall quality of life. Central to the pathology of PD are aggregates of alpha-synuclein protein and
The University of Manchester recently celebrated a significant milestone with the launch of the British Heart Foundation (BHF) Manchester Center of Research Excellence. Supported by a substantial £4 million grant from the BHF, this new center is set to advance world-class cardiovascular research
Antibody-drug conjugates (ADCs) are emerging as a groundbreaking approach in oncology, offering the potential to revolutionize cancer treatment through targeted and effective therapies. This innovation combines the precision of targeted antibodies with the potent cell-killing ability of
The concept of using the body's own immune system to combat cancer, known as immunotherapy, has undergone significant evolution over the past decade. Initially deemed a novel approach for treating a limited patient demographic with advanced cancer types, immunotherapy now stands as a fundamental
